1 week Ago By Defense World Staff
Wells Fargo & Company MN lifted its stake in shares of Arcellx, Inc. (NASDAQ:ACLX – Free Report) by 35.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission.
The fund owned 26,638 shares of the company’s stock after buying an additional 7,002 shares during the period. Wells Fargo & Company MN’s holdings in Arcellx were worth $2,043,000 at the end of the most recent quarter. Other hedge funds have also bought and sold shares of the company.
Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Arcellx by 9.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,836 shares of the company’s stock worth $754,000 after purchasing an additional 858 shares during the period.
Lord Abbett & CO. LLC increased its stake in shares of Arcellx by 2.1% during the third quarter.
Lord Abbett & CO. LLC now owns 891,848 shares of the company’s stock valued at $74,478,000 after purchasing an additional 18,004 shares in the last quarter. Swiss National Bank boosted its stake in Arcellx by 0.
8% in the 4th quarter. Swiss National Bank now owns 63,400 shares of the company’s stock worth $4,862,000 after purchasing an additional 500 shares in the last quarter. Avanza Fonder AB purchased a new position in shares of Arcellx in the fourth quarter worth $184,000.
Finally, Rhumbline Advisers lifted its position in Arcellx by 1.9% during the fourth quarter. Rhumbline Advisers now owns 59,903 shares of the company’s stock valued at $4,594,000 after purchasing an additional 1,125 shares during the period.
96.03% of the stock is currently owned by institutional investors. Insider ActivityIn other news, Director Kavita Patel sold 1,500 shares of the business’s stock in a transaction on Tuesday, March 18th.
The shares were sold at an average price of $71.64, for a total transaction of $107,460.00.
The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Rami Elghandour sold 38,300 shares of Arcellx stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $62.
02, for a total value of $2,375,366.00. Following the completion of the sale, the insider now owns 149,186 shares of the company’s stock, valued at $9,252,515.
72. The trade was a 20.43 % decrease in their ownership of the stock.
The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,455 shares of company stock worth $3,408,458. 6.
24% of the stock is currently owned by insiders. Arcellx Trading Down 0.4 %ACLX opened at $63.
71 on Friday. The company has a market cap of $3.50 billion, a price-to-earnings ratio of -89.
73 and a beta of 0.33. The company’s 50 day moving average is $64.
77 and its 200 day moving average is $74.88. Arcellx, Inc.
has a 12-month low of $47.88 and a 12-month high of $107.37.
Arcellx (NASDAQ:ACLX – Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.
63) by ($0.24). The business had revenue of $15.
27 million during the quarter, compared to analysts’ expectations of $27.42 million. Arcellx had a negative return on equity of 8.
28% and a negative net margin of 25.94%. As a group, analysts predict that Arcellx, Inc.
will post -1.58 EPS for the current fiscal year. Arcellx Company Profile (Free Report)Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).Featured ArticlesFive stocks we like better than ArcellxStock Ratings and Recommendations: Understanding Analyst RatingsShort Sellers Gave Up on These 3 Names RecentlyGrowth Investing: Should You Adopt This Investing Strategy in 2022?3 Boring Stocks Outperforming the Market This YearThe Basics of Support and ResistanceIf You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy.
